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Abstract
Fluconazole – antimycotic belonging to the first generation azoles – 
is widely used as treatment for invasive candidiasis and candidemia in 
numerous clinical settings as Neonatal Intensive Care Unit (NICU) and 
adult Intensive Care Unit (ICU), as well as oncology, onco-hematology and 
solid organ transplantation. More recently use of antimycotics has spread to 
medical divisions, where fungal infections represent an emerging problem 
due to population’s ageing, malnourishment and important comorbidities. 
Fluconazole is effective against numerous Candida species, particularly 
against albicans, tropicalis and parapsilosis strains. On the other hand, C. 
krusei is intrinsically resistant to fluconazole and C. glabrata can be sensitive 
or resistant in a dose dependent fashion. Epidemiological variability is 
noteworthy and depends on the geographical location of the institution, the 
clinical setting, and the frequency and intensity of fluconazole employment 
for invasive candidiasis. In many ICUs fluconazole sensitive C. albicans 
is cultured in 50% of positive samples, while the remaining 50% show 
growth of variably sensitive fungal species, often resistant to fluconazole. 
Due to increasingly frequent emergence of resistant strains of Candida spp., 
American guidelines (IDSA) in 2009, and European ones (ESCMID) in 
2012, recommended substitution of fluconazole with echinocandines as first 
line therapy in patients with severe disease, as defined by an APACHE II 
score greater than 15. Thus fluconazole must be limited to low risk cases, 
treatment of sensitive strains and de-escalation from echinocandin therapy, 
after microbiological diagnosis and drug resistance profile characterization.
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Pharmacological profile of Fluconazole
Due to its efficacy and safety for prolonged 
use – even at high dosages – fluconazole has been 
extensively used as first line drug in prophylaxis 
and treatment of invasive candidiasis [1, 2]. It’s 
a fungistatic agent that acts inhibiting selectively 
fungal cytochrome P450 (CYP)-dependent enzyme 
lanosterol 14α-demethylase, causing depletion of 
cell membrane ergosterol, an essential component 
of fungal cell wall. Inhibition of ergosterol 
synthesis impairs membrane fluidity, and leads 
to accumulation of toxic 14α-methylated sterols, 
resulting in growth arrest and eventual fungal cell 
death [3, 4]. It is active against 90% of Candida 
species. Nevertheless, increasing drug resistance 
has been witnessed, especially towards less 
common species (Tab. 1). Among strains most 
frequently isolated in ICU, C. krusei appears to 
be intrinsically resistant to fluconazole, while C. 
glabrata can be resistant or sensitive in a dose 
related fashion. Fluconazole exists both in oral 
and intravenous formulations and shows – as its 
azoles congeners – an excellent oral availability, 
linear pharmacokinetics unaffected by gastric 
pH nor content [6, 7]. It is hydrophilic, with low 
protein bounded fraction (11-13%) and a volume 
of distribution (DV) equal to total body water [6]. 
An important feature of the drug is its capacity 
to concentrate in cerebrospinal fluid, as much as 
50-60% of plasmatic concentration: this makes it 
useful in treatment of Candida spp. infections of 
the central nervous system [7]. When administered 
at its standard dosages of 200-400 mg/die, 11% 
of fluconazole undergoes hepatic metabolism, 
while 80% is excreted unmodified with urine [8]. 
Drug’s plasmatic half-life ranges from 30 hours in 
patients with normal renal function to 90 or more 
hours in patients with creatinine clearance lower 
than 20 ml/min. It is therefore easy to understand 
that its posology has to be opportunely reduced 
in patients affected by renal failure. Generally, in 
patients with creatinine clearance from 20 to 60 ml/
min, a 50% dose reduction – obtained halving the 
dose or doubling administration intervals – is to be 
considered adequate. Moderate inhibition of CYP 
3A4, CYP 2C8/9 and CYP 2C19 must be taken into 
account, especially in patients assuming complex 
therapies (as ICU patients generally are), which 
could interfere. Clinical efficacy correlates tightly 
with area under the curve (AUC) of concentration 
over a 24 hour time span, divided by minimal 
inhibiting concentration (MIC) for fluconazole. 
Animal studies enlightened that with azoles, an 
AUC/MIC ratio of 25 is necessary to obtain 50% 
of maximal efficacy. An AUC/MIC ratio from 25 to 
50 is required to obtain a mean drug concentration 
equal to twice the MIC [9]. Azoles have a 
narrow therapeutic range, thus overlooking their 
pharmacokinetics most likely makes the eventuality 
of plasmatic levels either below the range of efficacy 
or oppositely too elevated (possible toxic adverse 
reactions). Fluconazole posology for an adult with 
normal renal function, requires a loading dose of 12 
Table 1. Candida species sensitivity to antifungal drugs. Modified from Pappas et al., 2009 [5].
Candida species Fluconazole Voriconazole Anphotericine B Echinocandin
Candida albicans S S S S
Candida glabrata From S-DD to R From  S-DD to R From S to I S
Candida tropicalis S S S S
Candida parapsilosis S S S From S to R
Candida krusei R S From S to I R
Candida lusitaniae S S From S to R S
Candida guillermondii From S to R From S to R From S to R From I to R
S: sensitive; DD: dose dependant; R: resistant; I: intermediate. 
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mg/kg followed by a daily dose of 6 mg/kg. The dose 
is halved when creatinine clearance is less than 
60 ml/min. Monitoring plasma concentration is 
usually unnecessary and can be done occasionally 
when considered useful to improve the therapeutic 
effect [10]. The empiric use of fluconazole (before 
microbiological identification of the specific strain 
and its drug sensitivity is available) is becoming 
increasingly risky, given the frequent finding of 
non albicans strains in ICU patients biological 
samples [11, 12].
Invasive candidiasis epidemiology in ICU
Candidemia is the fourth cause of blood stream 
infection in ICU patients in North America [13]. 
Similar data are found in Europe. A recent French 
study observed that 33% of ICU patients presents 
candidemia, invasive candidiasis or both [14]. 
A multicenter prospective, observational study 
conducted in 38 Italian ICUs between 2006-2008 
showed a median rate of candidemia of 10.08 per 
1,000 admissions, 40% of them were sustained 
by non albicans species [15]. Candida species 
diffusion can be differently distributed among 
various institutions, as well as their characteristic 
sensitivity and resistance to fluconazole. In the 
last two decades many institutions witnessed the 
progressive reduction in incidence of C. albicans, 
paralleled by the increment of non albicans 
species, which in some ICU represent the 50% of 
isolated specimens. More frequently isolated non 
albicans species are C. parapsilosis, C. glabrata, 
C. tropicalis and C. krusei [14]. Less frequently 
C. lusitaniae, C. guillermondii e C. rugosa are 
the isolated species. C. glabrata and tropicalis are 
rare in NICU, while C. parapsilosis accounts for 
as much as 30% in this setting [16, 17]. Numerous 
studies have been carried out to justify the reasons 
why there has been a shift in the prevalence 
from C. albicans to non albicans species in ICU 
environment. Extensive fluconazole use is one of 
the possible causes, for the increased resistance to 
the drug as well as for the progressive substitution 
of albicans species with non albicans drug resistant 
strains as principal etiologic agent of infection. 
Furthermore wide use of intravascular devices and 
parenteral hypernutrition are possible causes for 
infection by emerging non albicans species [18, 19]. 
Though any hospitalized patient can suffer from 
Candida spp. infection, subjects affected by cancer, 
hematologic disease or immunodeficiency are 
more prone to it. Usually infection is endogenous, 
moving from skin or mucous membranes into the 
bloodstream then disseminating throughout the 
organism [20]. Another cause of proliferation and 
diffusion of fungi in non neutropenic patients, 
is the wide use of broad-spectrum antibacterial 
therapy. In ICU patients many risk factors have 
been identified, such as trauma, parenteral nutrition, 
intravascular catheters, immunosuppressive drugs 
and corticosteroids, skin or intestinal barrier 
damage. The last two in particular, are extremely 
relevant (Tab. 2). Candidemia diagnosis is based 
on repeated hematic cultures. Culture sensitivity 
is not optimal and time span to obtain a diagnosis 
is often prolonged in many institutions. Among 
new proposed exams, only b-D-glucan is cited as a 
diagnostic tool for candidemia in IDSA guidelines 
[5]. Though considered promising, till now no 
controlled studies have been carried out on its 
efficacy and elevated costs and false positive rates 
among ICU patients may limit its utility. 




All patients Abdominal surgery, intravascular 
catheters, total parenteral nutrition, 
broad spectrum antibiotics, 
immunosuppression and corticosteroids, 
acute kidney injury, diabetes, solid organ 
trasplantation, hemodialysis, acute 
pancreatitis
ICU patients Prolonged stay (> 96 h), candida 
colonization (expecially if multifocal), 
high APACHE II score, low birth weight 
(neonatal intensive care unit)
Table 2. Risk factors for candida infection in ICU. Modified 
from Bassetti et al., 2010 [21].
Therapy of candidiasis
As it takes a long time to have a certain 
diagnosis, strategies to begin appropriate therapy as 
soon as possible in patients at high risk for Candida 
spp. infections or probably infected have been 
developed. These are represented by antimycotic 
drug prophylaxis in patients at risk for infection, 
and empiric and preemptive therapy. Antimycotic 
prophylaxis is well documented in settings such as 
oncology, oncohematology and neonatology, while 
guidelines do not recommend it for candidosis and 
candidemia prevention in ICU [5], although studies 
reporting a reduction in fungal infections in patients 
under prophylaxis can be found in literature. No 
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clear mortality reduction has been proven by these 
studies. Disadvantages of fluconazole prophylaxis 
include toxicity from prolonged use, environmental 
selective pressure on local flora and emergence of 
resistant strains [22]. Fluconazole prophylaxis is 
only recommended in specific ICUs, with a rate of 
infection superior to 1-2% and in patients at high 
risk for infection [5]. Empiric therapy, defined 
as administration of antimycotics in presence of 
persistent fever refractory to therapy, has been 
proposed in order to anticipate treatment and reduce 
mortality in neutropenic and non neutropenic 
patients [5]. This approach can cause a significant 
and not always necessary increment in the number 
of treated cases. So preemptive therapy appears till 
now more promising. It is defined as the introduction 
of antifungal therapy when specific risk factors 
are identified: ICU stay > 96 h, broad-spectrum 
antibiotic therapy, severe sepsis, gastrointestinal 
surgery, total parenteral nutrition, clinical evidence 
for multifocal Candida spp. colonization or positive 
b-D-glucan assay. This strategy is meant to permit 
an early treatment in high risk cases while avoiding 
many unnecessary treatments [21]. Nevertheless, 
though promising, its efficacy still needs to be proven 
by clinically and statistically adequate prospective 
studies. In cases documented by positive cultures – 
if an antimycogram is available – treatment is easier. 
The drug of choice is the one characterized by the 
highest sensitivity, lowest adverse reaction rate 
and severity and lowest cost. Unfortunately, even 
when bloodstream invasion has been documented, 
exact Candida spp. characterization and sensitivity 
are not always available in short time. For these 
reasons and according to epidemiological data 
documenting a constant increase in the incidence 
rate of non albicans species and fluconazole 
resistant strains, 2009 ISDA and 2012 ESCMID 
guidelines [23] extend to high risk non neutropenic 
patients the recommendation of echinocandins as 
first line drugs for treatment of invasive candidiasis 
and candidemia. In patients characterized by 
moderate-severe disease, high APACHE II score, 
hemodynamic instability and likely cardiac 
involvement, echinocandins are recommended due 
to their high fungicidal activity on Candida spp. 
strains. Therapy can be modified later, according to 
sensitivity demonstrated by cultural exams, shifting 
to fluconazole in stable sensitive to treatment patients 
[5, 24, 25]. Echinocandins are contraindicated in C. 
parapsilosis infections, as resistance by this strain 
has been reported [26]. It is important to remember 
that after cultures become negative and important 
clinical improvement is obtained, oral antifungal 
therapy is recommended for the next 14 days, with 
single most suitable drug for Candida single species 
(step down therapy). Two more issues must be kept 
in mind when dealing with treatment of a mycotic 
infection. Though a clinical trial conducted on 842 
adult patients failed to demonstrate any benefit 
from early removal of intravascular catheters [27], 
guidelines and expert opinions judge necessary and 
wise removal of intravascular devices when blood 
cultures are positive for Candida spp. The second 
problem is represented by the fact that many Candida 
species produce biofilm, significantly contributing 
to their virulence and persistence of infection [28]. 
Biofilm producing strains show higher resistance to 
fluconazole therapy and respond better to treatment 
with amphotericine B than echinocandins [29].
Conclusions
Candida infections are increasing worldwide 
and are becoming a frequent cause of disease 
not only in ICU or oncohematologic settings, 
but even in medical divisions, among the elder 
malnourished population and in patients affected 
by chronic obstructive pulmonary disease. Mycotic 
infection epidemiology is evolving and non 
albicans fluconazole-resistant strains are emerging. 
Fluconazole is still useful in treatment of many 
Candida spp. strains and can be used in low risk 
patients and in institutions where resistant strains 
have not emerged. In moderate-severe risk patients, 
or in hospitals where resistant strains are frequently 
isolated, echinocandins must be considered as 
first line treatment, and eventually substituted 
only after patient stabilization and isolation and 
characterization of the responsible fungus. Oral 
therapy with fluconazole or other appropriate azoles 
(step-down) – if active against isolated strain – 
can be considered when blood cultures become 
negative. There is still not complete agreement on 
optimal management for ICU patients with suspect 
candidemia. Prophylaxis is not recommended, as 
it exposes to risk of unnecessary treatment and is 
a likely cause of emergence of resistant strains. 
Empiric therapy based on local epidemiology 
and severity of illness is a widely used approach, 
but implies as well a high number of unnecessary 
treatments. Preemptive treatment seems to be 
promising, as it minimizes the risk of late treatment 
and reduces the number of patients treated 
unnecessarily. Low sensibility of blood cultures and 
the long time they require to be performed make 
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desirable the development of biomarkers of fungal 
infections. B-D-glucan is promising but no studies 
have clearly demonstrated its potentialities.
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